| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 南微医学科技股份有限公司主要从事微创医疗器械的研发、制造和销售。秉持着“以科技和创新服务临床”的宗旨以及“守正创新、匠心致远”的发展理念,公司致力于帮助全球医疗机构提高医疗水平,减少病人痛苦,降低医疗支出。 经过20余年的创新发展,公司逐步形成了内镜诊疗、肿瘤介入、微创神经外科三大产品系列,成为微创诊疗领域具有较高科研创新实力和市场竞争优势、业绩高速增长的细分行业领先企业。 自成立以来,公司始终坚持创新与全球化双轮驱动,拥有一支高素质、国际化、多学科交叉的核心技术团队和全球营销团队。公司及公司主要技术人员先后获得国家科技进步奖二等奖2次、国家技术发明奖二等奖1次、省部级科技奖项16次,拥有国内外发明专利103项。公司先后在美国、德国、荷兰、英国、法国、日本、葡萄牙、瑞士、泰国等地设立全资子公司并在国内建有10余个营销分中心,正在形成覆盖全球主要市场的营销网络,产品及服务可及90多个国家和地区。 | ||||||||||||||||||||||||
| Main Business | 微创医疗器械的研发、制造和销售。 | ||||||||||||||||||||||||
| Legal Representative | 隆晓辉 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 龚星亮 | ||||||||||||||||||||||||
| Solicitors | 北京金诚同达律师事务所 | ||||||||||||||||||||||||
| Auditors | 中天运会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
| Tel No | 025-58648819 | ||||||||||||||||||||||||
| Fax No | - | ||||||||||||||||||||||||
| Website | www.micro-tech.com.cn/ | ||||||||||||||||||||||||
| nwyx@mtmed.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 22/07/2019 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 3.050 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 1.500 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 21.988 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 15.385B |
![]() |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |